English

IRULYA THERAPEUTICS INC.

EDGAR

CRTX Current report (8-K) · filed 2026-10-19

43 filing records in this dataset, filed from 2019-04-12 to 2026-10-19. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 116 million USD 2026-06-30 Source
Exact value

115981000 USD
Long-term debt including current maturities: 0 USD 2025-12-31 Source
Exact value

0 USD
Shares outstanding: 1.02 million shares 2026-06-30 Source
Exact value

1017063 shares

Reported share-count change

-98.10% · -52.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

53624180 shares · 2025-06-30· Source
1017063 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-92.5 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -13442000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -83979000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -44521000 USD · 2025-01-01 – 2025-09-30 Source
Net income: 35912000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -75488000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-46.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -30944000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21016000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -41425000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -30944000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -7627000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -26514000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -7627000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

78 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 348000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 274000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 352000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 348000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-47 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -30944000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21016000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -41425000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -30944000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -7627000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -26514000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -7627000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 348000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 274000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 352000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 348000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-19.

Financial data available through: 2025-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2025-12-31
Shares outstanding: 8 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 27.15 million

Prior period

−USD 56.83 million

2024-01-01 – 2024-12-31
Current period

−USD 83.98 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-83979000 − -56828000 = -27151000 USD

-56828000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-83979000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · IRULYA THERAPEUTICS INC. · 2025-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Year-over-year change in Net income: -27151000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -83979000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#3017022 Filing: 000119312526151364 Input fundies:NetIncome: -56828000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#3018769 Filing: 000119312526151364
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 9.52 million

Prior period

−USD 31.9 million

2024-01-01 – 2024-12-31
Current period

−USD 41.43 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-41425000 − -31904000 = -9521000 USD

-31904000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-41425000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · IRULYA THERAPEUTICS INC. · 2025-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Year-over-year change in Operating cash flow: -9521000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -41425000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1528455 Filing: 000119312526151364 Input fundies:OperatingCashFlow: -31904000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1530310 Filing: 000119312526151364
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+37%

Prior period

USD 257,000

2024-01-01 – 2024-12-31
Current period

USD 352,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

352000 − 257000 = 95000 USD

257000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
352000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · IRULYA THERAPEUTICS INC. · 2025-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Year-over-year change in Capital expenditure: 95000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 352000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1543198 Filing: 000119312526151364 Input fundies:CapitalExpenditure: 257000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1545041 Filing: 000119312526151364
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 12.48 million Exact value Exact value: -12476000 USD 2018-01-01 – 2018-12-31: -12476000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IRULYA THERAPEUTICS INC. · 2018-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Net Income: -12476000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12476000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000156459021009867/crtx-20201231.xml#142212 Filing: 000156459021009867 The citation records this snapshot. The page link may show a newer release later.	−USD 11.7 million Exact value Exact value: -11695000 USD 2018-01-01 – 2018-12-31: -11695000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IRULYA THERAPEUTICS INC. · 2018-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Operating Cash Flow: -11695000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11695000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000156459021009867/crtx-20201231.xml#174074 Filing: 000156459021009867 The citation records this snapshot. The page link may show a newer release later.	USD 212,000 Exact value Exact value: 212000 USD 2018-01-01 – 2018-12-31: 212000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IRULYA THERAPEUTICS INC. · 2018-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Capital Expenditure: 212000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 212000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000156459021009867/crtx-20201231.xml#175941 Filing: 000156459021009867 The citation records this snapshot. The page link may show a newer release later.	−USD 11.91 million Calculation and evidence -11695000 − 212000 USD Exact free cash flow: -11907000 USD 2018-01-01 – 2018-12-31: -11695000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 212000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IRULYA THERAPEUTICS INC. · 2018-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Free cash flow: -11907000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11695000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000156459021009867/crtx-20201231.xml#174074 Filing: 000156459021009867 Input fundies:CapitalExpenditure: 212000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000156459021009867/crtx-20201231.xml#175941 Filing: 000156459021009867 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 36.98 million Exact value Exact value: -36980000 USD 2019-01-01 – 2019-12-31: -36980000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IRULYA THERAPEUTICS INC. · 2019-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Net Income: -36980000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -36980000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017022002571/crtx-20211231.htm#3408083 Filing: 000095017022002571 The citation records this snapshot. The page link may show a newer release later.	−USD 33.28 million Exact value Exact value: -33277000 USD 2019-01-01 – 2019-12-31: -33277000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IRULYA THERAPEUTICS INC. · 2019-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Operating Cash Flow: -33277000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33277000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017022002571/crtx-20211231.htm#1975123 Filing: 000095017022002571 The citation records this snapshot. The page link may show a newer release later.	USD 55,000 Exact value Exact value: 55000 USD 2019-01-01 – 2019-12-31: 55000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IRULYA THERAPEUTICS INC. · 2019-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Capital Expenditure: 55000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 55000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017022002571/crtx-20211231.htm#1998032 Filing: 000095017022002571 The citation records this snapshot. The page link may show a newer release later.	−USD 33.33 million Calculation and evidence -33277000 − 55000 USD Exact free cash flow: -33332000 USD 2019-01-01 – 2019-12-31: -33277000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 55000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IRULYA THERAPEUTICS INC. · 2019-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Free cash flow: -33332000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33277000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017022002571/crtx-20211231.htm#1975123 Filing: 000095017022002571 Input fundies:CapitalExpenditure: 55000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017022002571/crtx-20211231.htm#1998032 Filing: 000095017022002571 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 76.85 million Exact value Exact value: -76849000 USD 2020-01-01 – 2020-12-31: -76849000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IRULYA THERAPEUTICS INC. · 2020-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Net Income: -76849000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -76849000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017022002571/crtx-20211231.htm#3406046 Filing: 000095017022002571 The citation records this snapshot. The page link may show a newer release later.	−USD 50.82 million Exact value Exact value: -50818000 USD 2020-01-01 – 2020-12-31: -50818000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IRULYA THERAPEUTICS INC. · 2020-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Operating Cash Flow: -50818000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -50818000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017022002571/crtx-20211231.htm#1972979 Filing: 000095017022002571 The citation records this snapshot. The page link may show a newer release later.	USD 52,000 Exact value Exact value: 52000 USD 2020-01-01 – 2020-12-31: 52000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IRULYA THERAPEUTICS INC. · 2020-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Capital Expenditure: 52000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 52000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017022002571/crtx-20211231.htm#1995901 Filing: 000095017022002571 The citation records this snapshot. The page link may show a newer release later.	−USD 50.87 million Calculation and evidence -50818000 − 52000 USD Exact free cash flow: -50870000 USD 2020-01-01 – 2020-12-31: -50818000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 52000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IRULYA THERAPEUTICS INC. · 2020-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Free cash flow: -50870000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -50818000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017022002571/crtx-20211231.htm#1972979 Filing: 000095017022002571 Input fundies:CapitalExpenditure: 52000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017022002571/crtx-20211231.htm#1995901 Filing: 000095017022002571 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 89.95 million Exact value Exact value: -89945000 USD 2021-01-01 – 2021-12-31: -89945000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IRULYA THERAPEUTICS INC. · 2021-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Net Income: -89945000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -89945000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017023008148/qncx-20221231.htm#3574514 Filing: 000095017023008148 The citation records this snapshot. The page link may show a newer release later.	−USD 62.93 million Exact value Exact value: -62932000 USD 2021-01-01 – 2021-12-31: -62932000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IRULYA THERAPEUTICS INC. · 2021-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Operating Cash Flow: -62932000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -62932000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017023008148/qncx-20221231.htm#1856839 Filing: 000095017023008148 The citation records this snapshot. The page link may show a newer release later.	USD 180,000 Exact value Exact value: 180000 USD 2021-01-01 – 2021-12-31: 180000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IRULYA THERAPEUTICS INC. · 2021-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Capital Expenditure: 180000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 180000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017023008148/qncx-20221231.htm#1883202 Filing: 000095017023008148 The citation records this snapshot. The page link may show a newer release later.	−USD 63.11 million Calculation and evidence -62932000 − 180000 USD Exact free cash flow: -63112000 USD 2021-01-01 – 2021-12-31: -62932000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 180000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IRULYA THERAPEUTICS INC. · 2021-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Free cash flow: -63112000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -62932000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017023008148/qncx-20221231.htm#1856839 Filing: 000095017023008148 Input fundies:CapitalExpenditure: 180000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017023008148/qncx-20221231.htm#1883202 Filing: 000095017023008148 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 51.66 million Exact value Exact value: -51660000 USD 2022-01-01 – 2022-12-31: -51660000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IRULYA THERAPEUTICS INC. · 2022-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Net Income: -51660000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51660000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017024039440/qncx-20231231.htm#3281779 Filing: 000095017024039440 The citation records this snapshot. The page link may show a newer release later.	−USD 44.04 million Exact value Exact value: -44038000 USD 2022-01-01 – 2022-12-31: -44038000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IRULYA THERAPEUTICS INC. · 2022-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Operating Cash Flow: -44038000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44038000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017024039440/qncx-20231231.htm#1850663 Filing: 000095017024039440 The citation records this snapshot. The page link may show a newer release later.	USD 133,000 Exact value Exact value: 133000 USD 2022-01-01 – 2022-12-31: 133000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IRULYA THERAPEUTICS INC. · 2022-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Capital Expenditure: 133000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 133000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017024039440/qncx-20231231.htm#1872925 Filing: 000095017024039440 The citation records this snapshot. The page link may show a newer release later.	−USD 44.17 million Calculation and evidence -44038000 − 133000 USD Exact free cash flow: -44171000 USD 2022-01-01 – 2022-12-31: -44038000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 133000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IRULYA THERAPEUTICS INC. · 2022-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Free cash flow: -44171000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44038000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017024039440/qncx-20231231.htm#1850663 Filing: 000095017024039440 Input fundies:CapitalExpenditure: 133000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000095017024039440/qncx-20231231.htm#1872925 Filing: 000095017024039440 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 31.39 million Exact value Exact value: -31385000 USD 2023-01-01 – 2023-12-31: -31385000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IRULYA THERAPEUTICS INC. · 2023-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Net Income: -31385000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31385000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000166277425000012/qncx-20241231.htm#2069990 Filing: 000166277425000012 The citation records this snapshot. The page link may show a newer release later.	−USD 18.29 million Exact value Exact value: -18292000 USD 2023-01-01 – 2023-12-31: -18292000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IRULYA THERAPEUTICS INC. · 2023-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Operating Cash Flow: -18292000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18292000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000166277425000012/qncx-20241231.htm#1399496 Filing: 000166277425000012 The citation records this snapshot. The page link may show a newer release later.	USD 160,000 Exact value Exact value: 160000 USD 2023-01-01 – 2023-12-31: 160000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IRULYA THERAPEUTICS INC. · 2023-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Capital Expenditure: 160000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 160000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000166277425000012/qncx-20241231.htm#1408463 Filing: 000166277425000012 The citation records this snapshot. The page link may show a newer release later.	−USD 18.45 million Calculation and evidence -18292000 − 160000 USD Exact free cash flow: -18452000 USD 2023-01-01 – 2023-12-31: -18292000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 160000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IRULYA THERAPEUTICS INC. · 2023-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Free cash flow: -18452000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18292000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000166277425000012/qncx-20241231.htm#1399496 Filing: 000166277425000012 Input fundies:CapitalExpenditure: 160000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000166277425000012/qncx-20241231.htm#1408463 Filing: 000166277425000012 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 56.83 million Exact value Exact value: -56828000 USD 2024-01-01 – 2024-12-31: -56828000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IRULYA THERAPEUTICS INC. · 2024-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Net Income: -56828000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -56828000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#3018769 Filing: 000119312526151364 The citation records this snapshot. The page link may show a newer release later.	−USD 31.9 million Exact value Exact value: -31904000 USD 2024-01-01 – 2024-12-31: -31904000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IRULYA THERAPEUTICS INC. · 2024-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Operating Cash Flow: -31904000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31904000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1530310 Filing: 000119312526151364 The citation records this snapshot. The page link may show a newer release later.	USD 257,000 Exact value Exact value: 257000 USD 2024-01-01 – 2024-12-31: 257000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IRULYA THERAPEUTICS INC. · 2024-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Capital Expenditure: 257000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 257000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1545041 Filing: 000119312526151364 The citation records this snapshot. The page link may show a newer release later.	−USD 32.16 million Calculation and evidence -31904000 − 257000 USD Exact free cash flow: -32161000 USD 2024-01-01 – 2024-12-31: -31904000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 257000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IRULYA THERAPEUTICS INC. · 2024-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Free cash flow: -32161000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -31904000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1530310 Filing: 000119312526151364 Input fundies:CapitalExpenditure: 257000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1545041 Filing: 000119312526151364 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 83.98 million Exact value Exact value: -83979000 USD 2025-01-01 – 2025-12-31: -83979000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IRULYA THERAPEUTICS INC. · 2025-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Net Income: -83979000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83979000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#3017022 Filing: 000119312526151364 The citation records this snapshot. The page link may show a newer release later.	−USD 41.43 million Exact value Exact value: -41425000 USD 2025-01-01 – 2025-12-31: -41425000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IRULYA THERAPEUTICS INC. · 2025-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Operating Cash Flow: -41425000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41425000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1528455 Filing: 000119312526151364 The citation records this snapshot. The page link may show a newer release later.	USD 352,000 Exact value Exact value: 352000 USD 2025-01-01 – 2025-12-31: 352000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IRULYA THERAPEUTICS INC. · 2025-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Capital Expenditure: 352000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 352000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1543198 Filing: 000119312526151364 The citation records this snapshot. The page link may show a newer release later.	−USD 41.78 million Calculation and evidence -41425000 − 352000 USD Exact free cash flow: -41777000 USD 2025-01-01 – 2025-12-31: -41425000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 352000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IRULYA THERAPEUTICS INC. · 2025-12-31 IRULYA THERAPEUTICS INC. (edgar:1662774) Free cash flow: -41777000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:00:44Z Snapshot: b475aa27e1fc831acc5861e98f9674bff8ceed3af57138f9421315d546d66330 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1662774?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41425000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1528455 Filing: 000119312526151364 Input fundies:CapitalExpenditure: 352000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm#1543198 Filing: 000119312526151364 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

43 filings · 1,870 latest values · 1,870 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001662774, 1662774, CRTX, IRLA, QNCX, edgar:1662774

Also known as Cortexyme, Inc., IRULYA THERAPEUTICS INC., IRulya Therapeutics Inc., QUINCE THERAPEUTICS, INC., Quince Therapeutics, Inc.

IRULYA THERAPEUTICS INC.

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation